Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells which still remains incurable despite conventional and high-dose chemotherapies. With the introduction of new agents, such as bortezomib, thalidomide, and lenalidomide, there has been significant improvement in treatment outcomes for MM during the last decade. Furthermore, several new novel agents those off...
متن کاملTargeted therapy in multiple myeloma.
BACKGROUND Multiple myeloma (MM) is an incurable malignancy. Recent insights into its biology has allowed the use of novel therapies targeting not only the deregulated intracellular signaling in MM cells but also its interaction with the bone marrow microenvironment that confers drug resistance, growth, and survival advantage to the malignant cells. METHODS We review and summarize the recent ...
متن کاملMonoclonal Gammopathies Molecular therapy for multiple myeloma
Evidence and Information Sources. Identification of novel, MM-specific molecular targets should pave the way for drugs that can specifically attack the neoplastic cells while sparing the normal ones. Drugs that alter the marrow microenvironment – such as bisphosphonates, proteasome inhibitors (e.g. PS-341/LDP341), lactacystin or LLNV compounds – induce apoptosis or G1 growth arrest and alter th...
متن کاملTargeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoclonal antibodies (mAbs) and/or cytotoxic T lymphocytes (CTLs) are now attracting much attention a...
متن کاملFGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.
Gain-of-function mutations in FGF receptor 3 (FGFR3) have been implicated in severe skeletal dysplasias and in a variety of cancers. In their study in this issue of the JCI, Qing et al. used specific shRNA probes to demonstrate that FGFR3 functions as an important driver of bladder carcinoma cell proliferation (see the related article beginning on page 1216). A unique anti-FGFR3 mAb was shown t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Medicine
سال: 2013
ISSN: 2161-1025
DOI: 10.4172/2161-1025.s2-002